Janeway's immunobiology

10TH EDITION

Kenneth Murphy
Washington University School of Medicine, Saint Louis

Casey Weaver
University of Alabama at Birmingham Heersink School of Medicine

Leslie Berg
University of Colorado Anschutz School of Medicine

With contribution by:
Gregory Barton
University of California, Berkeley



W. W. NORTON & COMPANY
Independent Publishers Since 1923

Contents in Brief

PREFACE iii
What's New in the Tenth Edition iv
Resources for Instructors and Students vi
Acknowledgments vii
About the Authors ix

PART I AN INTRODUCTION TO IMMUNOBIOLOGY AND INNATE IMMUNITY
Chapter 1 Basic Concepts in Immunology 1
Chapter 2 Innate Immunity: The First Lines of Defense 37
Chapter 3 Cellular Mechanisms of Innate Immunity 79

PART II THE RECOGNITION OF ANTIGEN
Chapter 4 Antigen Recognition by B-cell and T-cell Receptors 141
Chapter 5 The Generation of Lymphocyte Antigen Receptors 179
Chapter 6 Antigen Presentation to T Lymphocytes 217

PART III THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES
Chapter 7 Lymphocyte Receptor Signaling 261
Chapter 8 The Development of B and T Lymphocytes 301

PART IV THE ADAPTIVE IMMUNE RESPONSE
Chapter 9 T Cell–Mediated Immunity 347
Chapter 10 The Humoral Immune Response 405
Chapter 11 Integrated Dynamics of Innate and Adaptive Immunity 453
Chapter 12 The Barrier Immune System 505

PART V THE IMMUNE SYSTEM IN HEALTH AND DISEASE
Chapter 13 Failures of Host Defense Mechanisms 587
Chapter 14 Allergic Diseases and Hypersensitivity Reactions 663
Chapter 15 Autoimmunity and Transplantation 699
Chapter 16 Manipulation of the Immune Response 749

APPENDICES
Note: Appendices II-IV are available on digital.wwnorton.com/janeway10 and in the ebook.
Appendix I The Immunologist's Toolbox A-1
eAppendix II CD Antigens A-49
eAppendix III Cytokines and Their Receptors A-69
eAppendix IV Chemokines and Their Receptors A-73

Glossary G-1
Credits C-1
Index I-1

Detailed Contents

Preface iii

What's New in the Tenth Edition iv

Resources for Instructors and Students vi

Acknowledgments vii

About the Authors ix

PART I AN INTRODUCTION TO IMMUNOBIOLOGY AND INNATE IMMUNITY

Chapter 1 Basic Concepts in Immunology 1

The origins of vertebrate immune cells. 2

Principles of innate immunity. 3

1-1 Commensal organisms cause little host damage while pathogens damage host tissues by a variety of mechanisms. 3

1-2 Anatomic and chemical barriers are the first defense against pathogens. 5

1-3 The immune system is activated by inflammatory inducers that indicate the presence of pathogens or tissue damage. 6

1-4 The myeloid lineage comprises most of the cells of the innate immune system. 7

1-5 Sensor cells express pattern-recognition receptors that provide an initial discrimination between self and nonself. 8

1-6 Sensor cells induce an inflammatory response by producing mediators such as chemokines and cytokines. 9

1-7 Innate lymphoid cells and natural killer cells are effector cells that share similarities with lymphoid lineages of the adaptive immune system. 11

Summary. 11

Principles of adaptive immunity. 11

1-8 The interaction of antigens with antigen receptors induces lymphocytes to acquire effector and memory activity. 12

1-9 Antibodies and T-cell receptors are composed of constant and variable regions that provide distinct functions. 13

1-10 Antibodies and T-cell receptors recognize antigens by fundamentally different mechanisms. 13

1-11 Antigen-receptor genes are assembled by somatic gene rearrangements of incomplete receptor gene segments. 14

1-12 Lymphocytes activated by antigen give rise to clones of antigen-specific effector cells that mediate adaptive immunity. 15

1-13 Lymphocytes with self-reactive receptors are normally eliminated during development or are functionally inactivated. 16

1-14 Lymphocytes mature in the bone marrow or the thymus and then congregate in lymphoid tissues throughout the body. 16

1-15 Adaptive immune responses are initiated by antigen and antigen-presenting cells in peripheral lymphoid tissues. 17

1-16 Lymphocytes encounter and respond to antigen in the peripheral lymphoid organs. 18

1-17 Mucosal surfaces have specialized immune structures that orchestrate responses to environmental microbial encounters. 20

1-18 Lymphocytes activated by antigen proliferate in the peripheral lymphoid organs, generating effector cells and immunological memory. 22

Summary. 24

The effector mechanisms of immunity. 25

1-19 Innate immune responses can select from several effector modules to protect against different types of pathogens. 26

1-20 Antibodies protect against extracellular pathogens and their toxic products. 27

1-21 T cells orchestrate cell-mediated immunity and regulate B-cell responses to most antigens. 29

1-22 Inherited and acquired defects in the immune system result in increased susceptibility to infection. 31

1-23 Understanding adaptive immune responses is important for the control of allergies, autoimmune disease, and the rejection of transplanted organs. 32

1-24 Vaccination is the most effective means of controlling infectious diseases. 33

1-25 Emerging pathogens present new challenges for the immune system. 33

Summary. 34

Summary to Chapter 1. 35

References. 35

Chapter 2 Innate Immunity: The First Lines of Defense 37

Anatomic barriers and initial chemical defenses. 38

2-1 Infectious diseases are caused by diverse living agents that replicate in their hosts. 38

2-2 Epithelial surfaces of the body provide the first barrier against infection. 42

2-3 Infectious agents must overcome innate host defenses to establish a focus of infection. 44

2-4 Epithelial cells and phagocytes produce several kinds of antimicrobial molecules. 45

Summary. 49

The complement system and innate immunity. 49

2-5 The complement system recognizes features of microbial surfaces and marks them for destruction by coating them with C3b. 51

2-6 The lectin pathway uses soluble receptors that recognize microbial surfaces to activate the complement cascade. 54

2-7 The classical pathway is initiated by activation of the C1 complex and is homologous to the lectin pathway. 57

2-8 Complement activation is largely confined to the surface on which it is initiated. 58

2-9 The alternative pathway is an amplification loop for C3b formation that is accelerated by properdin in the presence of pathogens. 59
2-10 Membrane and plasma proteins that regulate the formation and stability of C3 convertases determine the extent of complement activation. 61
2-11 Complement developed early in the evolution of multicellular organisms. 62
2-12 Surface-bound C3 convertase deposits large numbers of C3b fragments on pathogen surfaces and generates C5 convertase activity. 63
2-13 Ingestion of complement-tagged pathogens by phagocytes is mediated by receptors for the bound complement proteins. 64
2-14 The small fragments of some complement proteins initiate a local inflammatory response. 66
2-15 The terminal complement proteins polymerize to form pores in membranes that can kill certain pathogens. 66
2-16 Complement-control proteins regulate all three pathways of complement activation and protect the host from their destructive effects. 68
2-17 Genetic and acquired disorders in complement regulation can produce various inflammatory conditions. 71
2-18 Pathogens produce several types of proteins that can inhibit complement activation. 73
Summary. 74
Summary to Chapter 2. 74
Discussion questions. 75
References. 75

Chapter 3 Cellular Mechanisms of Innate Immunity 79

Pathogen recognition by cells of the innate immune system. 79
3-1 After entering tissues, many microbes are recognized, ingested, and killed by phagocytes. 80
3-2 G protein–coupled receptors on phagocytes link microbe recognition with increased efficiency of intracellular killing. 83
3-3 Microbial recognition and tissue damage initiate an inflammatory response. 87
3-4 Toll-like receptors represent an ancient pathogen-recognition system. 90
3-5 Mammalian Toll-like receptors are activated by many different pathogen-associated molecular patterns. 90
3-6 TLR-4 recognizes bacterial lipopolysaccharide in association with the host accessory proteins MD-2 and CD14. 94
3-7 TLRs activate NFκB, AP-1, and IRF transcription factors to induce the expression of inflammatory cytokines and type I interferons. 95
3-8 The RIG-I–like receptors detect cytoplasmic viral RNAs and activate MAVS to induce type I interferon production and pro-inflammatory cytokines. 96
3-9 Cytosolic DNA activates the cGAS–STING pathway to induce production of type I interferons. 100
3-10 NLRs comprise a large family of intracellular sensors with diverse functions. 102
3-11 Certain NLR proteins react to infection or cellular damage by forming an inflammasome that induces cell death and secretion of inflammatory cytokines. 103
3-12 Activation of innate sensors in macrophages and dendritic cells triggers changes in gene expression that have far-reaching effects on the immune response. 106
3-13 Toll signaling in *Drosophila* is downstream of a distinct set of pathogen-recognition molecules. 107
3-14 TLR and NOD genes have undergone extensive diversification in both invertebrates and some primitive chordates. 108
Summary. 109

Consequences of innate immune activation. 109
3-15 Cytokines and their receptors fall into distinct families of structurally related proteins. 110
3-16 Cytokine receptors of the hematopoietin superfamily are associated with the JAK family of tyrosine kinases, which activate STAT transcription factors. 112
3-17 Chemokines released by macrophages and dendritic cells recruit effector cells to sites of infection. 114
3-18 Cell-adhesion molecules control interactions between leukocytes and endothelial cells during an inflammatory response. 116
3-19 Neutrophils make up the first wave of cells that cross the blood vessel wall to enter an inflamed tissue. 118
3-20 TNF-α is an important cytokine that triggers local containment of infection but induces shock when released systemically. 120
3-21 Cytokines made by macrophages and dendritic cells induce a systemic reaction known as the acute-phase response. 122
3-22 Interferons induced by viral infection make several contributions to host defense. 124
3-23 Several types of innate lymphoid cells provide protection in early infection. 126
3-24 NK cells are activated by type I interferon and macrophage-derived cytokines. 128
3-25 NK cells express activating and inhibitory receptors to distinguish between healthy and infected cells. 129
3-26 NK-cell receptors belong to several structural families. 130
3-27 NK cells express activating receptors that recognize ligands induced on infected cells or tumor cells. 133
Summary. 134
Summary to Chapter 3. 134
Discussion questions. 135
References. 136

PART II THE RECOGNITION OF ANTIGEN

Chapter 4 Antigen Recognition by B-cell and T-cell Receptors 141

The structure of a typical antibody molecule. 142
4-1 IgG antibodies consist of four polypeptide chains. 143
4-2 Immunoglobulin heavy and light chains are composed of constant and variable regions. 144

4-3 The domains of an immunoglobulin molecule have similar structures. 144
4-4 The antibody molecule can readily be cleaved into functionally distinct fragments. 146
4-5 The hinge region of the immunoglobulin molecule allows flexibility in binding to multiple antigens. 147
Summary. 147

Structural variation in immunoglobulin constant regions. 148
4-6 Different classes of immunoglobulins are distinguished by the structure of their heavy-chain constant regions. 148
4-7 The constant region confers functional specialization on the antibody. 150
4-8 IgM and IgA can form polymers by interacting with the J chain. 151
Summary. 152

The interaction of the antibody molecule with specific antigen. 152
4-9 Localized regions of hypervariable sequence form the antigen-binding site. 152
4-10 Antibodies bind antigens via contacts in CDRs that are complementary to the size and shape of the antigen. 153
4-11 Antibodies bind to conformational shapes on the surfaces of antigens using a variety of noncovalent forces. 155
4-12 Antibody interaction with intact antigens is influenced by steric constraints. 156
4-13 Some species generate antibodies with alternative structures. 157
Summary. 158

Antigen recognition by T cells. 159
4-14 The TCR$\alpha\beta$ heterodimer is very similar to a Fab fragment of immunoglobulin. 159
4-15 A T-cell receptor recognizes antigen in the form of a complex of a foreign peptide bound to an MHC molecule. 161
4-16 There are two classes of MHC molecules with distinct subunit compositions but similar three-dimensional structures. 162
4-17 Peptides are stably bound to MHC molecules and also serve to stabilize the MHC molecule on the cell surface. 164
4-18 MHC class I molecules bind short peptides of 8–10 amino acids by both ends. 165
4-19 The length of the peptides bound by MHC class II molecules is not constrained. 166
4-20 The crystal structures of several peptide:MHC:T-cell receptor complexes show a similar orientation of the T-cell receptor over the peptide:MHC complex. 168
4-21 The CD4 and CD8 cell-surface proteins of T cells directly contact MHC molecules and are required to make an effective response to antigen. 169
4-22 The two classes of MHC molecules are expressed differentially on cells. 172
4-23 A distinct subset of T cells bears an alternative receptor made up of γ and δ chains. 173
Summary. 174
Summary to Chapter 4. 174
Discussion questions. 175
References. 176

Chapter 5 The Generation of Lymphocyte Antigen Receptors 179

Primary immunoglobulin gene rearrangements and expression. 180
5-1 Complete immunoglobulin genes are generated by the somatic recombination of separate gene segments. 180
5-2 Multiple contiguous V gene segments are present at each immunoglobulin locus. 182
5-3 Rearrangement of V, D, and J gene segments is guided by flanking DNA sequences. 184
5-4 The reaction that recombines V, D, and J gene segments involves both lymphocyte-specific and ubiquitous DNA-modifying enzymes. 189
5-5 The diversity of the immunoglobulin repertoire is generated by four main processes. 190
5-6 The multiple inherited gene segments are used in different combinations. 191
5-7 Variable addition and subtraction of nucleotides at the junctions between gene segments contributes to the diversity of the third hypervariable region. 191
5-8 IgM and IgD are derived from the same pre-mRNA transcript and are both expressed on the surface of mature B cells. 193
5-9 Transmembrane and secreted forms of immunoglobulin are generated from different heavy-chain mRNA transcripts. 194
Summary. 196

T-cell receptor gene rearrangement. 196
5-10 The T-cell receptor gene segments are arranged in a pattern similar to that of immunoglobulin gene segments and are rearranged by the same enzymes. 196
5-11 T-cell receptors concentrate diversity in the third hypervariable region. 199
5-12 $\gamma\delta$ T-cell receptors are also generated by gene rearrangement. 200
Summary. 201

Evolution of the adaptive immune response. 201
5-13 Some invertebrates generate extensive diversity in a repertoire of immunoglobulin-like genes. 202
5-14 Agnathans possess an adaptive immune system that uses somatic gene rearrangement to diversify receptors built from LRR domains. 203
5-15 RAG-dependent adaptive immunity based on a diversified repertoire of immunoglobulin-like genes appeared abruptly in the cartilaginous fishes. 205
5-16 Different species generate immunoglobulin diversity in different ways. 207
5-17 Both $\alpha\beta$ and $\gamma\delta$ T-cell receptors are present in cartilaginous fishes. 210
5-18 MHC class I and class II molecules are also first found in the cartilaginous fishes. 210
Summary. 211
Summary to Chapter 5. 211

Discussion questions. 212
References. 213

Chapter 6 Antigen Presentation to T Lymphocytes 217

The generation of αβ T-cell receptor ligands. 218
6-1 Antigen presentation functions both in arming effector T cells and in triggering their effector functions to attack pathogen-infected cells. 218
6-2 Peptides are generated from ubiquitinated proteins in the cytosol by the proteasome. 220
6-3 Peptides from the cytosol are transported by TAP into the endoplasmic reticulum and further processed before binding to MHC class I molecules. 222
6-4 Newly synthesized MHC class I molecules are retained in the endoplasmic reticulum until they bind a peptide. 224
6-5 Dendritic cells use cross-presentation to present exogenous proteins on MHC class I molecules so as to prime CD8 T cells. 226
6-6 Peptide:MHC class II complexes are generated in acidified endocytic vesicles from proteins obtained through endocytosis, phagocytosis, and autophagy. 227
6-7 The invariant chain directs newly synthesized MHC class II molecules to acidified intracellular vesicles. 229
6-8 The MHC class II–like molecules HLA-DM and HLA-DO regulate exchange of CLIP for other peptides. 230
6-9 Cessation of MHC class II antigen processing occurs after dendritic-cell activation through reduced expression of the MARCH-1 E3 ligase. 233
Summary. 234

The major histocompatibility complex and its function. 235
6-10 Many proteins involved in antigen processing and presentation are encoded by genes within the MHC. 235
6-11 The protein products of MHC class I and class II genes are highly polymorphic. 238
6-12 MHC polymorphism affects antigen recognition by T cells by influencing both peptide binding and the contacts between the T-cell receptor and MHC molecule. 240
6-13 Alloreactive T cells recognizing nonself MHC molecules are very abundant. 243
6-14 Many T cells respond to superantigens. 245
6-15 MHC polymorphism extends the range of antigens to which the immune system can respond. 246
Summary. 246

Recognition of nonpeptide ligands by unconventional T-cell subsets. 247
6-16 A variety of genes with specialized functions in immunity are also encoded in the MHC. 247
6-17 Specialized MHC class I molecules act as ligands for the activation and inhibition of NK cells and unconventional T-cell subsets. 249
6-18 Members of the CD1 family of MHC class I–like molecules present lipid-based antigens to NKT cells. 251
6-19 The nonclassical MHC class I molecule MR1 presents microbial riboflavin metabolites to MAIT cells. 253
6-20 γδ T cells can recognize a variety of diverse ligands. 254
Summary. 255
Summary to Chapter 6. 255
Discussion questions. 256
References. 257

PART III THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES

Chapter 7 Lymphocyte Receptor Signaling 261

General principles of signal transduction and propagation. 261
7-1 Transmembrane receptors convert extracellular signals into intracellular biochemical events. 262
7-2 Intracellular signal propagation is mediated by large multiprotein signaling complexes. 263
7-3 Small G proteins act as molecular switches in many different signaling pathways. 264
7-4 Signaling proteins are recruited to the membrane by a variety of mechanisms. 265
7-5 Post-translational modifications of proteins can both activate and inhibit signaling responses. 266
7-6 The activation of many receptors generates small-molecule second messengers. 267
Summary. 268

Antigen receptor signaling and lymphocyte activation. 268
7-7 Antigen receptors consist of variable antigen-binding chains associated with invariant chains that carry out the signaling function of the receptor. 268
7-8 Antigen recognition by the T-cell receptor and its co-receptors transduces a signal across the plasma membrane to initiate signaling. 270
7-9 Antigen recognition by the T-cell receptor and its co-receptors leads to phosphorylation of ITAMs by Src family kinases, generating the first intracellular signal in a signaling cascade. 272
7-10 Phosphorylated ITAMs recruit and activate the tyrosine kinase ZAP-70. 273
7-11 ITAMs are also found in other receptors on leukocytes that signal for cell activation. 274
7-12 Activated ZAP-70 phosphorylates adaptor proteins and promotes PI 3-kinase activation. 275
7-13 Activated PLC-γ generates the second messengers diacylglycerol and inositol trisphosphate that lead to transcription factor activation. 276
7-14 Ca^{2+} entry activates the transcription factor NFAT. 277
7-15 Ras activation stimulates the mitogen-activated protein kinase (MAPK) relay and induces expression of the transcription factor AP-1. 278
7-16 Protein kinase C activates the transcription factors NFκB and AP-1. 280
7-17 PI 3-kinase activation up-regulates cellular metabolic pathways via the serine/threonine kinase Akt. 281
7-18 T-cell receptor signaling leads to enhanced integrin-mediated cell adhesion. 283
7-19 T-cell receptor signaling induces cytoskeletal reorganization by activating the small GTPase Cdc42. 283
7-20 The logic of B-cell receptor signaling is similar to that of T-cell receptor signaling, but some of the signaling components are specific to B cells. 285

7-21 Antigen receptor signaling is a dynamic process that evolves over time. 287
Summary. 288
Co-stimulatory and inhibitory receptors modulate antigen receptor signaling in T and B lymphocytes. 288
7-22 The cell-surface protein CD28 is a required co-stimulatory signaling receptor for naive T-cell activation. 289
7-23 Maximal activation of PLC-γ, which is important for transcription factor activation, requires a co-stimulatory signal induced by CD28. 290
7-24 TNF receptor superfamily members augment T-cell and B-cell activation. 291
7-25 Inhibitory receptors on lymphocytes down-regulate immune responses by interfering with co-stimulatory signaling pathways. 292
7-26 Inhibitory receptors on lymphocytes down-regulate immune responses by recruiting protein or lipid phosphatases. 293
7-27 Knowledge of lymphocyte receptor signaling pathways can be exploited to engineer chimeric antigen receptors. 295
Summary. 296
Summary to Chapter 7. 297
Discussion questions. 297
References. 298

Chapter 8 The Development of B and T Lymphocytes 301
Development of B lymphocytes. 303
8-1 Lymphocytes derive from hematopoietic stem cells in the bone marrow. 303
8-2 Commitment to B cell, T cell, or innate lymphoid cell lineages is regulated by distinct networks of transcription factors. 305
8-3 B-cell development begins by rearrangement of the heavy-chain locus. 305
8-4 The pre-B-cell receptor tests for successful production of a complete heavy chain and signals for the transition from the pro-B cell to the pre-B cell stage. 308
8-5 Pre-B-cell receptor signaling inhibits further heavy-chain locus rearrangement and enforces allelic exclusion. 310
8-6 Pre-B cells rearrange the light-chain locus and express cell-surface immunoglobulin. 310
8-7 Immature B cells are tested for autoreactivity before they leave the bone marrow. 312
8-8 Lymphocytes that encounter sufficient quantities of self antigens in the periphery are eliminated. 313
8-9 Newly formed B cells arriving in the spleen turn over rapidly and require cytokines and positive signals through the B-cell receptor for maturation and long-term survival. 314
8-10 B-1 B cells are an innate lymphocyte subset that arises early in development. 316
Summary. 317
Development of T lymphocytes. 319
8-11 T-cell progenitors originate in the bone marrow, but all the important events in T-cell development occur in the thymus. 320
8-12 T-cell precursors proliferate extensively in the thymus, but most die there. 321
8-13 Successive stages in the development of thymocytes are marked by changes in cell-surface molecules. 321
8-14 Commitment to the T-cell lineage occurs in the thymus after Notch signaling. 322
8-15 After T-cell commitment, thymocyte development is regulated by T-cell receptor rearrangement, expression, and signaling. 325
8-16 Thymocytes at different developmental stages are found in distinct parts of the thymus. 326
8-17 T cells with αβ or γδ receptors arise from a common progenitor. 326
8-18 T cells expressing γδ T-cell receptors arise in two distinct phases during development. 327
8-19 Successful synthesis of a rearranged β chain allows the production of a pre-T-cell receptor that triggers cell proliferation and blocks further β-chain gene rearrangement. 329
8-20 T-cell α-chain genes undergo successive rearrangements until positive selection or cell death intervenes. 331
Summary. 332
Positive and negative selection of T cells. 333
8-21 Overview of positive and negative selection of αβ lineage T cells. 333
8-22 Only thymocytes whose receptors interact with self peptide:self MHC complexes can survive and mature. 334
8-23 Positive selection coordinates the expression of CD4 or CD8 with the specificity of the T-cell receptor and the potential effector functions of the T cell. 335
8-24 Thymic cortical epithelial cells mediate positive selection of developing thymocytes. 337
8-25 T cells that react strongly with self antigens are deleted in the thymus. 338
8-26 The specificity and/or the strength of signals for negative and positive selection must differ. 339
8-27 αβ T cells diverge into multiple lineages at the $CD4^+$ and $CD8^+$ single-positive stage in the thymic medulla. 339
8-28 Thymic emigration is controlled by signaling through a G protein–coupled receptor. 340
8-29 T cells that encounter sufficient quantities of self antigens for the first time in the periphery are eliminated or inactivated. 341
Summary. 341
Summary to Chapter 8. 341
Discussion questions. 342
References. 343

PART IV THE ADAPTIVE IMMUNE RESPONSE

Chapter 9 T Cell–Mediated Immunity 347
Development and function of secondary lymphoid organs—sites for the initiation of adaptive immune responses. 349
9-1 Secondary lymphoid structures are specialized to facilitate the interaction of circulating T and B lymphocytes with antigen. 349

9-2 The development of secondary lymphoid tissues is initiated by lymphoid tissue inducer cells and cytokines of the tumor necrosis factor family. 351
9-3 T-cell entry into lymphoid tissues occurs across specialized small blood vessels and is mediated by the sequential actions of adhesion molecules and chemokine receptors. 353
9-4 T cells are highly motile within T-cell zones as they survey dendritic cells for cognate antigen. 356
9-5 The exit of T cells from T-cell zones of lymphoid tissues is controlled by a chemotactic lipid. 357
9-6 Activation of conventional dendritic cells stimulates their maturation and migration to T-cell zones to induce naive T-cell activation. 359
9-7 Subsets of conventional dendritic cells are specialized for different modes of antigen presentation. 364
Summary. 366
Naive T-cell activation, clonal expansion, and differentiation into effector and memory T cells. 367
9-8 Conventional dendritic cells deliver multiple signals for the activation of naive T cells. 368
9-9 T-cell activation induces metabolic changes that prepare the T cell for rapid clonal expansion and differentiation. 369
9-10 The rapid expression of interleukin-2 and the high-affinity component of its receptor allow activated T cells to respond to this cytokine coincident with entry into the cell cycle. 372
9-11 Additional co-stimulatory and inhibitory receptors are engaged after initial T-cell activation to control clonal expansion and contraction. 373
9-12 Proliferating T cells differentiate into effector T cells that are programmed for altered tissue homing and loss of a requirement for co-stimulation to act. 375
9-13 CD8 T cells can be activated in different ways to become cytotoxic effector cells. 376
9-14 CD4 T cells differentiate into several functionally distinct subsets. 378
9-15 Cytokines play a central role in guiding the differentiation of CD4 T cells down distinct pathways. 381
9-16 CD4 T-cell subsets can cross-regulate each other's differentiation through the cytokines they produce. 385
9-17 Regulatory T cells are a subset of CD4 T cells that restrains immune responses to maintain self-tolerance. 386
Summary. 388
General properties of effector T cells and their cytokines. 389
9-18 An immunological synapse can form between effector T cells and their targets to direct the release of effector molecules. 389
9-19 The effector functions of T cells are determined by the array of effector molecules they produce, which can act locally or at a distance. 391
9-20 Effector T cells express several TNF family cytokines. 392
Summary. 394
T cell–mediated cytotoxicity. 394
9-21 Cytotoxic T cells induce target cells to undergo programmed cell death via extrinsic or intrinsic pathways of apoptosis. 394
9-22 Cytotoxic effector proteins that trigger apoptosis are contained in the granules of cytotoxic CD8 T cells. 398
9-23 Cytotoxic T cells are selective serial killers of targets expressing a specific antigen. 399
9-24 Cytotoxic T cells also act by releasing cytokines. 400
Summary. 400
Summary to Chapter 9. 400
Discussion questions. 401
References. 402
Chapter 10 The Humoral Immune Response 405
B-cell activation by antigen and helper T cells. 406
10-1 Activation of B cells by antigen involves signals from the B-cell receptor and either helper T cells or microbial antigens. 406
10-2 Linked recognition of antigen by T cells and B cells promotes robust antibody responses. 408
10-3 B cells that encounter their antigens migrate toward the boundaries between B-cell and T-cell areas in secondary lymphoid tissues. 409
10-4 T cells express surface molecules and cytokines that activate B cells, which in turn promote T_{FH} cell development. 412
10-5 Some activated B cells differentiate into antibody-secreting plasmablasts and plasma cells. 413
10-6 The second phase of a primary B-cell immune response occurs when activated B cells migrate into follicles and proliferate to form germinal centers. 414
10-7 Germinal center B cells undergo V-region somatic hypermutation, and cells with mutations that improve affinity for antigen are selected. 417
10-8 Positive selection of germinal center B cells involves contact with T_{FH} cells and CD40 signaling. 419
10-9 Activation-induced cytidine deaminase introduces mutations into genes transcribed in B cells. 420
10-10 Mismatch and base-excision repair pathways contribute to somatic hypermutation after initiation by AID. 421
10-11 AID initiates class switching to allow the same assembled V_H exon to be associated with different C_H genes in the course of an immune response. 423
10-12 Cytokines made by T_H cells direct the choice of isotype for class switching in T-dependent antibody responses. 425
10-13 B cells that survive the germinal center reaction eventually differentiate into either plasma cells or memory cells. 426
10-14 Some antigens do not require T-cell help to induce antibody responses. 427
Summary. 429
The distributions and functions of immunoglobulin classes. 430
10-15 Antibodies of different classes operate in distinct places and have distinct effector functions. 431
10-16 Polymeric immunoglobulin receptor binds to the Fc regions of IgA and IgM and transports them across epithelial barriers. 432
10-17 The neonatal Fc receptor carries IgG across the placenta and prevents IgG excretion from the body. 433
10-18 High-affinity IgG and IgA antibodies can neutralize toxins and block the infectivity of viruses and bacteria. 434

10-19 Antigen:antibody complexes activate the classical pathway of complement by binding to C1q. 436
10-20 Complement receptors and Fc receptors both contribute to removal of immune complexes from the circulation. 438
Summary. 439
The destruction of antibody-coated pathogens via Fc receptors. 440
10-21 The Fc receptors of accessory cells are signaling receptors specific for immunoglobulins of different classes. 440
10-22 Fc receptors on phagocytes are activated by antibodies bound to the surface of pathogens and enable the phagocytes to ingest and destroy pathogens. 441
10-23 Fc receptors activate NK cells to destroy antibody-coated targets. 443
10-24 Mast cells and basophils bind IgE antibody via the high-affinity Fcε receptor. 444
10-25 IgE-mediated activation of accessory cells has an important role in resistance to parasite infection. 445
Summary. 446
Summary to Chapter 10. 446
Discussion questions. 447
References. 448
Chapter 11 Integrated Dynamics of Innate and Adaptive Immunity 453
Integration of innate and adaptive immunity in response to specific types of pathogens. 454
11-1 The course of an infection can be divided into several distinct phases. 454
11-2 The effector mechanisms that are recruited to clear an infection can be organized into immune modules. 458
11-3 Subsets of ILCs are early responders of the immune response. 460
Summary. 462
Effector CD4 T cells augment the effector functions of innate immune cells. 462
11-4 Effector T cells are guided to specific tissues and sites of infection by changes in their expression of adhesion molecules and chemokine receptors. 463
11-5 Pathogen-specific effector T cells are progressively enriched at sites of infection where they may undergo further maturation to acquire full effector function. 467
11-6 T_H1 cells coordinate and amplify the host response to intracellular pathogens through classical activation of macrophages. 467
11-7 Activation of macrophages by T_H1 cells must be tightly regulated to avoid tissue damage. 469
11-8 Chronic activation of macrophages by T_H1 cells mediates the formation of granulomas to contain intracellular pathogens that cannot be cleared. 471
11-9 Defects in type 1 immunity reveal its important role in the elimination of intracellular pathogens. 471
11-10 T_H2 cells coordinate type 2 responses to expel intestinal helminths and repair tissue injury. 472
11-11 T_H17 cells coordinate type 3 responses to enhance the clearance of extracellular bacteria and fungi. 475
11-12 Effector T cells continue to respond to maturational and maintenance signals as they carry out their effector functions in target tissues. 476
11-13 Effector T cells can be activated to release cytokines independently of antigen recognition. 478
11-14 Effector CD4 T cells demonstrate plasticity and cooperativity that enable adaptation during antipathogen responses. 479
11-15 Integration of cell- and antibody-mediated immunity is critical for protection against many types of pathogens. 480
11-16 Resolution of an infection is accompanied by the death of most effector T cells and persistence of a small number of long-lived memory T cells. 482
Summary. 483
Immunological memory. 484
11-17 Immunological memory is long lived after infection or vaccination. 484
11-18 MHC tetramers and adoptive transfers of clonal T-cell populations have enabled the study of T-cell memory. 485
11-19 The developmental origins of memory T cells parallel those of effector T cells. 486
11-20 Memory T cells are heterogeneous and include central memory, effector memory, and tissue-resident subsets. 488
11-21 Circulating memory T cells acquire heightened sensitivity to IL-7 and/or IL-15 and undergo metabolic reprogramming to survive long-term. 491
11-22 CD4 T-cell help is required for CD8 T-cell memory and involves CD40 and IL-2 signaling. 492
11-23 Memory B-cell responses are more rapid and have higher affinity for antigen compared with responses of naive B cells. 494
11-24 Memory B cells can reenter germinal centers and undergo additional somatic hypermutation and affinity maturation during secondary immune responses. 496
11-25 In immune individuals, secondary and subsequent responses are mainly attributable to memory lymphocytes. 496
Summary. 498
Summary to Chapter 11. 498
Discussion questions. 500
References. 500
Chapter 12 The Barrier Immune System 505
Organization of the mucosal immune system. 505
12-1 The mucosal immune system protects the internal surfaces of the body. 506
12-2 Immune cells of the mucosal immune system are located both within and outside of specialized lymphoid tissues in proximity to the epithelium. 510
12-3 Maturation of the gut-associated lymphoid tissue is driven by acquisition of the commensal microbiota. 516
Summary. 519
Innate immune defenses of the intestinal immune system. 520
12-4 The intestines are lined by a diversity of epithelial cell types that develop from a common progenitor and play distinct roles in mucosal immunity. 520

12-5 The intestinal epithelium contains conventional and unconventional T cells that are focused on barrier maintenance and defense. 528
12-6 Innate lymphoid cells and unconventional lymphocytes are present in GALT and in the lamina propria and are rapid responders to microbes that breach the epithelium. 534
Summary. 535
The role of adaptive immunity in regulating the intestinal mucosal immune system at homeostasis. 536
12-7 The mucosal immune system must establish and maintain tolerance to harmless foreign antigens. 536
12-8 Macrophages and dendritic cells have complementary roles in the maintenance of immune tolerance in the intestines. 537
12-9 The intestines have multiple routes for uptake and delivery of antigen to antigen-presenting cells. 540
12-10 Intestinal dendritic cells favor the induction of antigen-specific T_{reg} cells that are critical for the maintenance of mucosal immune homeostasis. 543
12-11 Lymphocytes primed within the mucosal immune system are directed to return to the mucosal tissue by tissue-specific adhesion molecules and chemokine receptors. 546
12-12 Secretory IgA is the dominant class of antibody associated with the mucosal immune system at homeostasis. 547
12-13 T cell–independent processes can contribute to IgA production in some species. 550
12-14 IgA deficiency is relatively common in humans but may be compensated for by secretory IgM. 551
12-15 Large numbers of antigen-experienced T cells are present in the intestinal lamina propria even in the absence of disease. 551
12-16 Priming of lymphocytes in one mucosal tissue may induce protective immunity at other mucosal surfaces. 552
Summary. 553
The intestinal immune response in host defense and immune-mediated disease. 553
12-17 Enteric pathogens elicit 'danger signals' by activating pattern-recognition receptors that are sequestered in the intestinal epithelium. 554
12-18 Pathogens induce inflammatory adaptive immune responses when innate defenses have been breached. 556
12-19 Effector T-cell responses in the intestine protect the function of the epithelium. 557
12-20 Noninvasive and invasive enteric bacterial pathogens use different strategies to colonize the intestines. 557
12-21 Dysregulated immune responses to commensal bacteria provoke intestinal disease. 563
Summary. 564
Immunity at other barrier tissues. 564
12-22 Anatomy and mucosal immunity of the airways. 564
12-23 Respiratory immunity to inhaled pathogens; respiratory viruses. 567
12-24 Cutaneous immunity. 574
12-25 The sensory nervous system communicates with the immune system to enhance defense against infections in the skin. 577
Summary. 579
Summary to Chapter 12. 580
Discussion questions. 581
References. 581

PART V THE IMMUNE SYSTEM IN HEALTH AND DISEASE

Chapter 13 Failures of Host Defense Mechanisms 587
Immunodeficiency diseases. 588
13-1 Primary immunodeficiency diseases are caused by inherited gene variants that typically cause recurrent infections early in life. 588
13-2 Defects in T-cell development can result in severe combined immune deficiencies. 589
13-3 SCID can also be due to defects in the purine salvage pathway. 592
13-4 Defects in antigen receptor gene rearrangement can result in SCID. 593
13-5 Defects in signaling from T-cell antigen receptors can cause severe immunodeficiency. 594
13-6 Genetic defects in thymic development or function that block T-cell development result in combined immunodeficiencies. 594
13-7 Defects in B-cell development result in deficiencies in antibody production that cause an inability to clear extracellular bacteria. 596
13-8 Combined immunodeficiencies (CIDs) can be caused by defects in T-cell differentiation and function that impair activation of B cells, dendritic cells and macrophages, and innate effector cells. 598
13-9 B cell–specific activation defects cause hyper IgM syndromes that are limited to defects in the antibody response. 600
13-10 Common variable immunodeficiency results from a variety of inherited defects that cause more limited defects in the antibody response. 600
13-11 Unidentified genetic defects cause isotype-specific antibody deficiencies. 601
13-12 Normal pathways for host defense against different infectious agents are pinpointed by genetic deficiencies of cytokine pathways central to type 1/T_H1 and type 3/T_H17 responses. 601
13-13 Inherited defects in the cytolytic pathway of lymphocytes can cause uncontrolled lymphoproliferation and inflammatory responses to viral infections. 603
13-14 X-linked lymphoproliferative syndrome is associated with fatal infection by Epstein–Barr virus and the development of lymphomas. 605
13-15 Immunodeficiency is caused by inherited defects in the development of dendritic cells. 606
13-16 Defects in complement components and complement-regulatory proteins cause defective humoral immune function and tissue damage. 607
13-17 Defects in phagocytic cells result in widespread bacterial infections. 608
13-18 Mutations in the molecular regulators of inflammation can cause uncontrolled inflammatory responses that result in 'autoinflammatory disease.' 612

13-19 Factor-replacement therapies, hematopoietic stem-cell transplantation, and gene therapy can be used successfully to correct genetic defects. 613
13-20 Noninherited, secondary immunodeficiencies are major predisposing causes of infection and death. 615
Summary. 616
Evasion and subversion of immune defenses. 616
13-21 Extracellular bacterial pathogens have evolved different strategies to avoid detection by pattern-recognition receptors and destruction by antibody, complement, and antimicrobial peptides. 617
13-22 Intracellular bacterial pathogens can evade the immune system by seeking shelter within phagocytes. 622
13-23 Immune evasion is also practiced by protozoan parasites. 623
13-24 Many viruses target type I and type III interferon pathways to impair host antiviral defense. 625
13-25 RNA viruses use different mechanisms of antigenic variation to keep a step ahead of the adaptive immune system. 625
13-26 DNA viruses use multiple mechanisms to subvert CTL and NK-cell responses. 628
13-27 Viruses that establish latency persist *in vivo* by ceasing to replicate until immunity wanes. 631
13-28 DNA and RNA viruses can induce exhaustion of CTL and NK cell responses, thereby impairing the antiviral response. 633
Summary. 633
Acquired immune deficiency syndrome. 634
13-29 HIV is a retrovirus that establishes a chronic infection that slowly progresses to AIDS. 636
13-30 HIV infects and replicates within cells of the immune system. 636
13-31 Activated CD4 T cells are the major source of HIV replication. 638
13-32 There are several routes by which HIV is transmitted and establishes infection. 641
13-33 HIV variants with tropism for different co-receptors play different roles in transmission and progression of disease. 641
13-34 A genetic deficiency of the co-receptor CCR5 confers resistance to HIV infection. 644
13-35 An immune response controls but does not eliminate HIV. 644
13-36 Lymphoid tissue is the major reservoir of HIV infection. 646
13-37 Genetic variation in the host can alter the rate of HIV disease progression. 647
13-38 The destruction of immune function as a result of HIV infection leads to increased susceptibility to opportunistic infection and eventually to death. 649
13-39 Drugs that block HIV replication lead to a rapid decrease in titer of infectious virus and an increase in CD4 T cells. 649
13-40 In the course of infection, HIV accumulates many mutations, which can result in the outgrowth of drug-resistant variants. 652
13-41 HIV treatment and prophylaxis are leading to a decline in the spread of HIV and AIDS. 652
13-42 Vaccination against HIV remains an attractive solution but poses many difficulties. 653
Summary. 655
Summary to Chapter 13. 656
Discussion questions. 656
References. 657
Chapter 14 Allergic Diseases and Hypersensitivity Reactions 663
IgE and IgE-mediated allergic diseases. 664
14-1 Sensitization involves class switching to IgE production on first contact with an allergen. 665
14-2 Although many types of antigens can cause allergic sensitization, proteases are common sensitizing agents. 666
14-3 Genetic factors contribute to the development of IgE-mediated allergic disease. 667
14-4 Environmental factors may interact with genetic susceptibility to cause allergic disease. 669
Summary. 671
Effector mechanisms in IgE-mediated allergic reactions. 671
14-5 Most IgE is cell-bound and engages effector mechanisms of the immune system by pathways different from those of other antibody isotypes. 671
14-6 Mast cells reside in tissues and orchestrate allergic reactions. 673
14-7 Eosinophils and basophils cause inflammation and tissue damage in allergic reactions. 675
14-8 IgE-mediated allergic reactions have a rapid onset but can also lead to chronic responses. 677
14-9 Allergen introduced into the bloodstream can cause anaphylaxis and urticaria. 679
14-10 Allergen inhalation is associated with the development of rhinitis and asthma. 681
14-11 Allergy to particular foods causes systemic reactions as well as symptoms limited to the gut. 682
14-12 IgE-mediated allergic disease can be treated by inhibiting effector pathways or by desensitization to restore biological tolerance. 684
Summary. 686
Non-IgE-mediated allergic diseases. 686
14-13 Non-IgE-dependent drug-induced hypersensitivity reactions in susceptible individuals occur by binding of the drug to the surface of circulating blood cells. 687
14-14 Systemic disease caused by immune-complex formation can follow the administration of large quantities of poorly catabolized antigens. 687
14-15 Hypersensitivity reactions can be mediated by T_H1 cells and cytotoxic CD8 T cells. 689
14-16 Celiac disease has features of both an allergic response and autoimmunity. 692
Summary. 694
Summary to Chapter 14. 694
Discussion questions. 695
References. 695
Chapter 15 Autoimmunity and Transplantation 699
The making and breaking of self-tolerance. 699
15-1 Multiple mechanisms normally contribute to prevent autoimmunity. 699

15-2 Lymphocytes that bind self antigens with relatively low affinity usually ignore them but in some circumstances become activated. 702
15-3 Antigens in immunologically privileged sites do not induce immune attack but can serve as targets. 703
15-4 Autoimmune responses can be controlled at various stages by regulatory T cells. 704
Summary. 705
Autoimmune diseases and pathogenic mechanisms. 706
15-5 Autoimmunity can be classified into either organ-specific or systemic disease. 706
15-6 Multiple components of the immune system are typically recruited in autoimmune disease. 707
15-7 Chronic autoimmune disease develops through positive feedback from inflammation, inability to clear the self antigen, and a broadening of the autoimmune response. 709
15-8 Both antibody and effector T cells can cause tissue damage in autoimmune disease. 711
15-9 Autoantibodies against blood cells promote their destruction. 713
15-10 The fixation of sublytic doses of complement to cells in tissues stimulates a powerful inflammatory response. 713
15-11 Autoantibodies against receptors cause disease by stimulating or blocking receptor function. 714
15-12 Autoantibodies against extracellular antigens cause inflammatory injury. 715
15-13 T cells specific for self antigens can cause direct tissue injury and sustain autoantibody responses. 717
Summary. 721
The genetic and environmental basis of autoimmunity. 721
15-14 Autoimmune diseases have a strong genetic component. 722
15-15 Monogenic defects of immune tolerance. 722
15-16 MHC genes have an important role in controlling susceptibility to autoimmune disease. 727
15-17 Genetic variants that impair innate immune responses can predispose to T cell–mediated chronic inflammatory disease. 727
15-18 Cross-reactivity between foreign molecules on pathogens and self molecules can promote autoimmune disease. 730
Summary. 731
Responses to alloantigens and transplant rejection. 732
15-19 Transplant rejection is mediated primarily by T-cell responses to MHG molecules. 732
15-20 Rejection of MHC-identical grafts is caused by peptides from other alloantigens bound to graft MHC molecules. 734
15-21 Alloreactive T cells reject transplanted organs by direct and indirect allorecognition. 735
15-22 Antibodies that react with endothelium cause hyperacute graft rejection. 737
15-23 Late failure of transplanted organs is caused by chronic injury to the graft. 737
15-24 A variety of organs are transplanted routinely in clinical medicine. 738
15-25 The converse of graft rejection is graft-versus-host disease. 740
15-26 The fetus is an allograft that is tolerated repeatedly. 741
Summary. 742
Summary to Chapter 15. 743
Discussion questions. 744
References. 744
Chapter 16 Manipulation of the Immune Response 749
Fighting infectious diseases with vaccination. 749
16-1 Vaccines can be based on attenuated pathogens or material from killed organisms. 750
16-2 Most effective vaccines generate antibodies that prevent damage caused by toxins or that neutralize pathogens and stop infection. 752
16-3 Effective vaccines must induce long-lasting protection while being safe and inexpensive. 753
16-4 Live-attenuated viral vaccines are usually more potent than 'killed' vaccines. 753
16-5 Live-attenuated viral vaccines can be made safer by the use of recombinant DNA technology. 754
16-6 Vaccines against bacteria or parasites can be developed using nonpathogenic or disabled bacteria or genetically attenuated parasites (GAPs). 755
16-7 Conjugate vaccines rely on linked recognition between T and B cells. 756
16-8 Adjuvants enhance the immunogenicity of vaccines, but few are approved for use in humans. 758
16-9 Protective immunity can be induced by RNA- and DNA-based vaccination. 759
16-10 The route of vaccination is an important determinant of success. 760
16-11 *Bordetella pertussis* vaccination illustrates the importance of the perceived safety of a vaccine. 761
16-12 Peptide-based vaccines can elicit protective immunity, but they require adjuvants and must be targeted to the appropriate cells and cell compartment to be effective. 762
16-13 Vaccination and checkpoint blockade may be useful in controlling existing chronic infections. 763
Summary. 763
Using the immune response to attack tumors. 764
16-14 The development of transplantable tumors in mice led to the discovery of protective immune responses to tumors. 764
16-15 Tumors are 'edited' by the immune system as they evolve and can escape rejection in many ways. 765
16-16 Tumor-rejection antigens can be recognized by T cells and form the basis of immunotherapies. 769
16-17 Checkpoint blockade can augment immune responses to existing tumors. 771
16-18 T cells expressing chimeric antigen receptors are an effective treatment in some leukemias. 773
16-19 Monoclonal antibodies against tumor antigens, alone or linked to toxins, can control tumor growth. 774
16-20 Enhancing the immune response to tumors by vaccination holds promise for cancer prevention and therapy. 776
Summary. 777

Treatment of unwanted immune responses. 778
16-21 Corticosteroids are powerful anti-inflammatory drugs that alter the transcription of many genes. 779
16-22 Cytotoxic drugs cause immunosuppression by killing dividing cells and have serious side effects. 780
16-23 Cyclosporin A, tacrolimus, and rapamycin are effective immunosuppressive agents that interfere with various T-cell signaling pathways. 781
16-24 JAK inhibitors can be used to treat autoimmune and inflammatory diseases. 783
16-25 Antibodies against cell-surface molecules can be used to eliminate lymphocyte subsets or to inhibit lymphocyte function. 783
16-26 Antibodies can be engineered to reduce their immunogenicity in humans. 784
16-27 Monoclonal antibodies can be used to prevent allograft rejection. 785
16-28 Depletion of autoreactive lymphocytes can treat autoimmune disease. 787
16-29 Biologics that block TNF-α, IL-1, or IL-6 can alleviate autoimmune diseases. 788
16-30 Biologics can block cell migration to sites of inflammation and reduce immune responses. 789
16-31 Blockade of co-stimulatory pathways that activate lymphocytes can be used to treat autoimmune disease. 790
16-32 Some commonly used drugs have immunomodulatory properties. 791
16-33 Controlled administration of antigen can be used to manipulate the nature of an antigen-specific response. 791
Summary. 792
Summary to Chapter 16. 792
Discussion questions. 794
References. 794

APPENDICES

Note: Appendices II–IV are available on digital.wwnorton.com/janeway10 and in the ebook.

Appendix I The Immunologist's Toolbox A-1
A-1 Immunization. A-1
A-2 Antibody responses. A-4
A-3 Affinity chromatography. A-5
A-4 Radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and competitive inhibition assay. A-5
A-5 Multiplex bead assay for detection of cytokines, antibody responses, or antigens. A-7
A-6 Hemagglutination and blood typing. A-8
A-7 Coombs tests and the detection of rhesus incompatibility. A-9
A-8 Monoclonal antibodies. A-11
A-9 Phage display libraries for antibody V-region production. A-12
A-10 Generation of human monoclonal antibodies from vaccinated individuals. A-13
A-11 Microscopy and imaging using fluorescent dyes. A-13
A-12 Immunoelectron microscopy. A-15
A-13 Immunohistochemistry. A-15
A-14 Immunoprecipitation and co-immunoprecipitation. A-16
A-15 Immunoblotting (western blotting). A-17
A-16 Use of antibodies in the isolation and characterization of multiprotein complexes by mass spectrometry. A-18
A-17 Isolation of peripheral blood lymphocytes by density-gradient fractionation. A-20
A-18 Isolation of lymphocytes from tissues other than blood. A-20
A-19 Flow cytometry and FACS analysis. A-21
A-20 Lymphocyte isolation using antibody-coated magnetic beads. A-23
A-21 Isolation of homogeneous T-cell lines. A-24
A-22 ELISPOT assay. A-24
A-23 Identification of functional subsets of T cells based on cytokine production or transcription factor expression. A-25
A-24 Identification of T or B lymphocytes on the basis of antigen receptor specificity. A-28
A-25 Biosensor assays for measuring the rates of association and dissociation of antigen receptors for their ligands. A-28
A-26 Assays of lymphocyte proliferation. A-30
A-27 Measurements of apoptosis. A-32
A-28 Assays for cytotoxic T cells. A-33
A-29 Assays for CD4 T cells. A-34
A-30 Transfer of protective immunity. A-35
A-31 Adoptive transfer of lymphocytes. A-36
A-32 Assessment of lymphocyte tissue residency by parabiosis. A-37
A-33 Hematopoietic stem-cell transfers. A-38
A-34 *In vivo* administration of antibodies. A-38
A-35 Transgenic mice. A-39
A-36 Gene knockout by targeted disruption. A-40
A-37 Knockdown of gene expression by RNA interference (RNAi). A-43
A-38 Cell-lineage tracing techniques. A-44
A-39 Single-cell analysis A-45

eAppendix II CD Antigens A-49
eAppendix III Cytokines and Their Receptors A-69
eAppendix IV Chemokines and Their Receptors A-73

Glossary G-1
Credits C-1
Index I-1